论文部分内容阅读
对许多侵袭粘膜表面的病原体而言,有效的疫苗必须能够诱导有效的粘膜免疫应答,为达到此目的,必须粘膜位置直接给药。然而,由于抗原吸收率过低等原因,许多经粘膜途径给予的抗原仅诱导低水平的免疫应答。为解决这一问题,可采用具有高度免疫原性的细菌肠毒素作为抗原载体。大肠杆菌不耐热肠毒素（LT）可作为多种抗原的佐剂,但是LT全毒素的A亚单位具有毒性,因此仅能应用LT的B亚单位（LTB）作为抗原佐剂。然而对诱导有效的粘膜免疫而言,LTB是必须同抗原物理结合还是作为粘膜佐剂与抗原一同给予仍存在许多争议,本研究旨在回答这一问题。
For many pathogens that attack the mucosal surface, an effective vaccine must be able to induce an effective mucosal immune response, which must be administered directly at the mucosal site for this purpose. However, many antigens administered by the mucosal route induce only a low level of immune response due to reasons such as low antigen absorption. To solve this problem, a highly immunogenic bacterial enterotoxin can be used as an antigen carrier. Escherichia coli heat-labile enterotoxin (LT) can serve as an adjuvant for multiple antigens, but the LT subunit A toxin is toxic and therefore only LT subunit B (LTB) can be used as an antigen adjuvant. However, there is much controversy over whether LTBs must be physically associated with antigens or administered as mucosal adjuvants to antigens in order to induce effective mucosal immunity. The purpose of this study was to answer this question.